Structured around development of highly effective, more tumor-specific monoclonal antibody (mAb) therapies, Welt Bio-Molecular Pharmaceutical LLC personnel are addressing design potent antibodiesable directly to induce a therapeutic effect -- not requiring use of toxic effector compounds -- and which do not cross-react with healthy tissues. Management's judgment is that such an approach allows for development of safer, more effective, and more affordable treatment options for targeted diseases. The firm's lead product -- mAb therapy for B-cell-derived leukemias and lymphomas -- has shown high specificity to, and efficacy in eradicating malignant B-cells. Principals of the firm are working towards completing pre-clinical requirements for this product, while expanding in-house mAb pipeline by discovering and targeting novel, biologically active epitopes in these and other cancers.
